MacroGenics, Inc. announced on August 13, 2025, the appointment of Eric Risser as President, Chief Executive Officer, and a member of the Board of Directors, effective immediately. This appointment formalizes the leadership transition previously announced in October 2024.
Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, where he oversaw key company functions and led corporate development efforts. Under his leadership, the company generated over $1.6 billion in non-dilutive capital since its inception.
Mr. Risser succeeds Scott Koenig, M.D., Ph.D., who stepped down after serving as President and Chief Executive Officer for 24 years. The Board expressed confidence in Mr. Risser's vision to lead MacroGenics into its next chapter, focusing on becoming a more capital-efficient biotechnology company delivering high-value therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.